Vertex Pharmaceuticals
Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About VRTX
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
VRTX Key Statistics
Stock Snapshot
As of today, Vertex Pharmaceuticals(VRTX) shares are valued at $434.02. The company's market cap stands at 110.14B, with a P/E ratio of 30.81.
As of 2025-11-17, Vertex Pharmaceuticals(VRTX) stock has fluctuated between $432.28 and $439.99. The current price stands at $434.02, placing the stock +0.4% above today's low and -1.4% off the high.
The Vertex Pharmaceuticals(VRTX)'s current trading volume is 1.3M, compared to an average daily volume of 1.51M.
During the past year, Vertex Pharmaceuticals(VRTX) stock moved between $362.50 at its lowest and $519.68 at its peak.
During the past year, Vertex Pharmaceuticals(VRTX) stock moved between $362.50 at its lowest and $519.68 at its peak.
VRTX News
Key Points Amazon has formidable moats and multiple avenues for growth. Enbridge offers stability, a generous dividend, and growth opportunities related to AI...
Vertex Pharmaceuticals (VRTX) is in focus after unveiling new clinical trial data for povetacicept in kidney diseases at a major conference. The company also se...
Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INCORPORATED (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our Twi...
Analyst ratings
62%
of 37 ratingsMore VRTX News
Vertex Pharmaceuticals recently reported positive interim data from the RUBY-3 trial at ASN Kidney Week 2025, showing that its investigational kidney disease th...
Maxim Group analyst Naz Rahman has maintained their neutral stance on VRTX stock, giving a Hold rating yesterday. Meet Your ETF AI Analyst Discover how TipRanks...
Even though Vertex Pharmaceuticals Incorporated's ( ) recent earnings release was robust, the market didn't seem to notice. We think that investors have missed...